Bristol-myers Squibb Compnay

Other

T Cell Sciences, Inc.

Smithkline Beecham Corporation

Avant Immunotherapeutics, Inc.

Michael L Gosselin

Tracy S Mitchell

Ray Camphausen

David Fabrizio

Dasa Lipovsek

Eric Steven Furfine

Sharon T Cload

Paul E Morin

Joanna F Swain

Simeon I Taylor

Guodong Chen

Aaron Paul Yamniuk

Henry C Marsh

Ranjan Mukherjee

Achal Mukundrao Pashine

Richard Yu-Cheng Huang

Priyanka Apurva Madia

Stephen Michael Carl

John Lifter

Richard A Smith

Chang-Jing Grace Yeh

Anne Mary Freeman

Derek A Holmes

Jonathan Harry Davis

Stanley Richard Krystek, Jr

Rex A Parker

Juhi Juneja

Ranjan Mukerjee

Rex Parker

Stanley Richard Krystek

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Nucleic acids encoding anti-TREM-1 antibodies

Anti-TREM-1 antibodies and uses thereof

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin bindingFn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Fast-off rate serum albumin binding fibronectin type III domains

The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-bindingFn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Serum albumin-binding fibronectin type III domains

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc&#x3b3;Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-bindingFn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Serum albumin binding molecules

A combination of a styrene reduction agent and a catalyst that effectively and economically reduces styrene emissions in Cured-In-Place Pipe, closed molding processes. The reduction agent generally comprises a calibrated mixture of salts including sodium chloride plus three persulfate salts: ammonium (APS), potassium (KPS), and sodium (NPS). These ingredients are combined in powder form and are compressed into soluble capsules containing calibrated amounts of the mixture. The capsule(s) may be prescribed through the use of software. The catalyst is hydrogen peroxide (HO). A calibrated amount of the styrene reduction agent capsule(s) are added to the cure water prior to starting the boiler equipment for the Cured-In-Place Pipe process, and this is followed by a calibrated amount of the HOcatalyst in order to reduce the residual monomer content in either process or waste streams.

Method and apparatus for controlling contamination from pipe coatings

A method and apparatus for combining multiple viscous fluids in which a desired, predetermined mixture ratio is automatically maintained by at least one system microcontroller. The microcontroller processes critical data relating to a primary fluid throughout a pumping and dispensing procedure, and automatically adjusts all additional flows based on changes to the primary fluid flow rate, temperature, pressure, viscosity, and pump characteristics by adjusting the speed of the motors driving pumps for all other fluids.

Proportional pump system for viscous fluids

Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid: mannose molar ratio of .gtoreq.0.25.

Preparation and use of sialylated glycoforms of soluble complement

Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.

Therapeutic methods employing sialylated glycoforms of soluble

Growing community of inventors

Boston, MA, United States of America

Michael L Gosselin